22 May 2013
Keywords: pfizer, starts, ph, iii, trials, tlc-d99, phase
Article | 19 December 1994
Two Phase III clinical trials in breast cancer patients have begun with
TLC-D99 (liposomal doxorubicin), a product being jointly developed ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
19 December 1994
12 December 1994
21 May 2013
© 2013 thepharmaletter.com